Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2025 Earnings Call Transcript November 13, 2025
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04.
Operator: Good afternoon, and welcome to Relmada Therapeutics, Inc. Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session. As a reminder, this conference call is...
